MedTrace Logo

Vandetanib Risk Minimisation Effectiveness

NCT01757470 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2016-08-31

No results posted yet for this study

Summary

Effectiveness of risk minimisation interventions for vandetanib in Canada

Conditions

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Clinical Sciences & Operations · Sanofi

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2014-02-28
Completion
2014-02-28

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01757470 on ClinicalTrials.gov